In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer

In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer

Background: For patients with human epidermal growth factor receptor-2 (HER2)-positive advanced or metastatic gastric cancer who have progressed on first-line trastuzumab therapy, the clinical value of the continuous use of trastuzumab beyond progression (TBP) is controversial. Objectives: The prese...

Descripció completa

Dades bibliogràfiques
Autors principals:	Hui Wang, Caiyun Nie, Weifeng Xu, Jing Li, He Gou, Huifang Lv, Beibei Chen, Jianzheng Wang, Yingjun Liu, Yunduan He, Jing Zhao, Xiaobing Chen
Format:	Article
Idioma:	English
Publicat:	SAGE Publishing 2024-04-01
Col·lecció:	Therapeutic Advances in Gastroenterology
Accés en línia:	https://doi.org/10.1177/17562848241245455

Ítems similars

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study
per: Caiyun Nie, et al.
Publicat: (2023-12-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
per: Shuhui You, et al.
Publicat: (2023-12-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
per: Sietske B.M. Gaykema, et al.
Publicat: (2014-07-01)

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
per: Negar Pourjamal, et al.
Publicat: (2025-03-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
per: Vildana Goga Çmega, et al.
Publicat: (2024-03-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
per: Muhammad Shahid Iqbal, et al.
Publicat: (2014-01-01)

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
per: Juin Park, et al.
Publicat: (2023-12-01)

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression
per: Yunus Emre Altıntaş, et al.
Publicat: (2024-12-01)

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
per: Azzurra Irelli, et al.
Publicat: (2024-01-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
per: Nu T. Lu, et al.
Publicat: (2015-09-01)

Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore
per: Yanting Ouyang, et al.
Publicat: (2024-11-01)

Trastuzumab and cardiotoxicity
per: Petra Sertić, et al.
Publicat: (2024-01-01)

The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature
per: Zhenpeng Wen, et al.
Publicat: (2024-10-01)

Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features
per: Zhida Wu, et al.
Publicat: (2025-01-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
per: Sara M Tolaney, et al.
Publicat: (2022-10-01)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
per: Yu Ishimine, et al.
Publicat: (2015-01-01)

Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy
per: Gi-Young Ha, et al.
Publicat: (2020-12-01)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
per: Gabriel L. Fiszman, et al.
Publicat: (2011-01-01)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
per: Eleni Triantafyllidi, et al.
Publicat: (2022-08-01)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
per: Page E. Blas, et al.
Publicat: (2024-03-01)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
per: Abul Azad, et al.
Publicat: (2025-01-01)

Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer
per: Zeyu Liu, et al.
Publicat: (2025-02-01)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
per: Hyun Jung Kwon, et al.
Publicat: (2023-05-01)

Resistance mechanisms and prospects of trastuzumab
per: Lizhe Wang, et al.
Publicat: (2024-11-01)

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
per: Jonathan Henricks, et al.
Publicat: (2025-02-01)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
per: Mohd Nafi, SN
Publicat: (2014)

Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
per: Patricia Miranda Romero, et al.
Publicat: (2015-02-01)

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
per: Dai Okemoto, et al.
Publicat: (2024-09-01)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
per: McLarty, K, et al.
Publicat: (2009)

821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
per: Edith A Perez, et al.
Publicat: (2023-11-01)

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
per: Chen Y, et al.
Publicat: (2024-07-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
per: Fei Xing, et al.
Publicat: (2023-01-01)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
per: Scott A Wu, et al.
Publicat: (2023-09-01)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
per: Ibrahim Sadek, et al.
Publicat: (2017-09-01)

Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report
per: Hua-Yang Pang, et al.
Publicat: (2025-01-01)

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
per: Caroline Rönnlund, et al.
Publicat: (2024-02-01)

Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
per: Taha Koray Sahin, et al.
Publicat: (2024-06-01)

Target Points in Trastuzumab Resistance
per: Sahar Shojaei, et al.
Publicat: (2012-01-01)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
per: Sylvana Hidalgo, et al.
Publicat: (2013-01-01)

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
per: Fei Xing, et al.
Publicat: (2024-01-01)